S

SCI Pharmtech Inc
TWSE:4119

Watchlist Manager
SCI Pharmtech Inc
TWSE:4119
Watchlist
Price: 94.9 TWD -1.15% Market Closed
Market Cap: 11.3B TWD
Have any thoughts about
SCI Pharmtech Inc?
Write Note

SCI Pharmtech Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SCI Pharmtech Inc
Cost of Revenue Peer Comparison

Comparables:
Y
3705
4746
1789
1795
1720

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
S
SCI Pharmtech Inc
TWSE:4119
Cost of Revenue
-NT$904.5m
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
1%
Y
YungShin Global Holding Corp
TWSE:3705
Cost of Revenue
-NT$4.2B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
-3%
Formosa Laboratories Inc
TWSE:4746
Cost of Revenue
-NT$2.6B
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
-2%
ScinoPharm Taiwan Ltd
TWSE:1789
Cost of Revenue
-NT$2.1B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Cost of Revenue
-NT$7.7B
CAGR 3-Years
-2%
CAGR 5-Years
-15%
CAGR 10-Years
-24%
Standard Chem & Pharm Co Ltd
TWSE:1720
Cost of Revenue
-NT$3.7B
CAGR 3-Years
-15%
CAGR 5-Years
-12%
CAGR 10-Years
-8%

See Also

What is SCI Pharmtech Inc's Cost of Revenue?
Cost of Revenue
-904.5m TWD

Based on the financial report for Jun 30, 2024, SCI Pharmtech Inc's Cost of Revenue amounts to -904.5m TWD.

What is SCI Pharmtech Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
1%

Over the last year, the Cost of Revenue growth was -12%. The average annual Cost of Revenue growth rates for SCI Pharmtech Inc have been 4% over the past three years , 7% over the past five years , and 1% over the past ten years .

Back to Top